ABSTRACT
A nasal type extranodal NK/T-cell lymphoma (ENKL) is very rare in children. A pediatric nasal type ENKL is generally localized and is likely to have sensitivity to radiotherapy. The most common site is the upper airway tract, such as nasal region, Waldeyer's ring, paranasal sinuses and palates. It usually presents with nasal symptoms, such as obstruction or epistaxis. We describe our experience of concurrent chemoradiotherapy in a 13-year old boy having incidentally detected nasal type ENKL on laryngoscopic examination who did not have nasal symptoms. He received three cycles of dexamethasone (40 mg/day for 3 days), ifosfamide (1,000 mg/m2/day for 3 days), VP-16 (67 mg/m2/day for 3 days) and carboplatin (200 mg/m2 for 1 day) at 3-week intervals and 45 Gy intensity-modulated radiation therapy. He has been disease-free for 18 months after cessation of therapy.
Subject(s)
Child , Humans , Male , Carboplatin , Chemoradiotherapy , Dexamethasone , Epistaxis , Etoposide , Ifosfamide , Lymphoma , Palate , Paranasal Sinuses , RadiotherapyABSTRACT
A nasal type extranodal NK/T-cell lymphoma (ENKL) is very rare in children. A pediatric nasal type ENKL is generally localized and is likely to have sensitivity to radiotherapy. The most common site is the upper airway tract, such as nasal region, Waldeyer's ring, paranasal sinuses and palates. It usually presents with nasal symptoms, such as obstruction or epistaxis. We describe our experience of concurrent chemoradiotherapy in a 13-year old boy having incidentally detected nasal type ENKL on laryngoscopic examination who did not have nasal symptoms. He received three cycles of dexamethasone (40 mg/day for 3 days), ifosfamide (1,000 mg/m2/day for 3 days), VP-16 (67 mg/m2/day for 3 days) and carboplatin (200 mg/m2 for 1 day) at 3-week intervals and 45 Gy intensity-modulated radiation therapy. He has been disease-free for 18 months after cessation of therapy.